The company will start a phase 2/3 trial of PF-08634404 in March.
ApexOnco Front Page
Recent articles
Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.
After beating "historical" Xtandi masofaniten fails to beat actual Xtandi.
October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.
The group goes after a KRAS-related target on which Boehringer recently gave up.
Conferences ramp up, and ASH abstracts near.
Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.
